Together with santésuisse, Interpharma has initiated the stakeholder project SwissHTA, which has the backing of the Swiss Medical Association (FMH) and the Swiss Academy of Medical Science (SAMS) with the federal government in the role of observer. A consensus was worked out here for the drafting of Health Technology Assessments (HTAs) in Switzerland. In 2015, SwissHTA formally joined the sponsoring association of the Swiss Medical Board (SMB), after a convergence process had been initiated in 2014 in order to unify the approaches of these two projects to the way benefits are assessed.

Proposals of Interpharma for a broad-based approach

In May 2016, the Federal Council decided to reinforce the HTAs and to have medical services systematically and regularly assessed for their benefits. Interpharma had advocated that the originally intended federal law on a centre for quality in compulsory health insurance, which was to have conducted not only quality assurance reviews but also HTAs, should not be pursued any further, after numerous stakeholders – including Interpharma – had voiced their criticism in the consultation process. The areas of Quality and HTAs are now to be handled separately. The Federal Office of Public Health (FOPH) will also set up an HTA unit of its own. Stakeholders can submit proposals on health services to be examined. Interpharma has submitted several proposals both for 2016 and for 2017 and also commented on HTA reports. The questions submitted pursue a comprehensive approach to reduce inappropriate provision, overprovision and underprovision. Interpharma has argued for years in favour of this kind of broad approach.